Pigmented infundibulocystic basal cell carcinoma: A diagnostic challenge in dark skin.

Abstract

1. Curry JL, Tetzlaff MT, Nagarajan P et al. Diverse types of dermatologic toxicities from immune checkpoint blockade therapy. J. Cutan. Pathol. 2017; 44: 158–76. 2. Wang LL, Patel G, Chiesa-Fuxench ZC et al. Timing of onset of adverse cutaneous reactions associated with programmed cell death protein 1 inhibitor therapy. JAMA Dermatol. 2018; 154: 1057–61. 3. Zitouni NB, Arnault J-P, Dadban A et al. Subacute cutaneous lupus erythematosus induced by nivolumab: two case reports and a literature review. Melanoma Res. 2019; 29: 212–5. 4. Liu RC, Sebaratnam DF, Jackett L et al. Subacute cutaneous lupus erythematosus induced by nivolumab. Australas J. Dermatol. 2018; 59: e152–4. 5. Blakeway EA, Elshimy N, Muinonen-Martin A et al. Cutaneous lupus associated with pembrolizumab therapy for advanced melanoma: a report of three cases. Melanoma Res. 2019; 29: 338–41. doi: 10.1111/ajd.13540